Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations ; volume:485 ; number:4 ; day:27 ; month:8 ; year:2024 ; pages:631-642 ; date:10.2024
Virchows Archiv ; 485, Heft 4 (27.8.2024), 631-642, 10.2024
- Creator
-
Armbruster, Hannes
Schotte, Tilman
Götting, Isabell
Overkamp, Mathis
Granai, Massimo
Volmer, Lea Louise
Bahlinger, Veronika
Matovina, Sabine
Koch, André
Dannehl, Dominik
Engler, Tobias
Hartkopf, Andreas
Brucker, Sara
Bonzheim, Irina
Fend, Falko
Staebler, Annette
Montes-Mojarro, Ivonne
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00428-024-03897-3
- URN
-
urn:nbn:de:101:1-2501182112400.665135506633
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Armbruster, Hannes
- Schotte, Tilman
- Götting, Isabell
- Overkamp, Mathis
- Granai, Massimo
- Volmer, Lea Louise
- Bahlinger, Veronika
- Matovina, Sabine
- Koch, André
- Dannehl, Dominik
- Engler, Tobias
- Hartkopf, Andreas
- Brucker, Sara
- Bonzheim, Irina
- Fend, Falko
- Staebler, Annette
- Montes-Mojarro, Ivonne
- SpringerLink (Online service)
Other Objects (12)
The impact of single tumor cell dissemination on individualized systemic breast cancer treatment
Tucatinib (Tukysa) bei HER2-positivem Brustkrebs : hochwirksame Behandlungsoption für metastasierte Patienten, auch bei ZNS-Metastasierung
Trastuzumab-Deruxtecan (Enhertu) - Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
Trastuzumab deruxtecan (Enhertu®) : Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
Circulating and Disseminated Tumor Cells in Breast Carcinoma : Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019
Update breast cancer 2023 Part 1 – early stage breast cancer
Attrition in the first three therapy lines in patients with advanced breast cancer in the German real-world PRAEGNANT registry
Circulating and Disseminated Tumour Cells in Breast Carcinoma : Report from the Consensus Conference on Tumour Cell Dissemination during the 38th Annual Meeting of the German Society of Senology, Berlin, 14 June 2018
The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service
HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma
MEKK2 mediates aberrant ERK activation in neurofibromatosis type I
Reply to “CRISPR screens are feasible in TP53 wild‐type cells”
The impact of single tumor cell dissemination on individualized systemic breast cancer treatment
Tucatinib (Tukysa) bei HER2-positivem Brustkrebs : hochwirksame Behandlungsoption für metastasierte Patienten, auch bei ZNS-Metastasierung
Trastuzumab-Deruxtecan (Enhertu) - Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
Trastuzumab deruxtecan (Enhertu®) : Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
Circulating and Disseminated Tumor Cells in Breast Carcinoma : Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019
Update breast cancer 2023 Part 1 – early stage breast cancer
Attrition in the first three therapy lines in patients with advanced breast cancer in the German real-world PRAEGNANT registry
Circulating and Disseminated Tumour Cells in Breast Carcinoma : Report from the Consensus Conference on Tumour Cell Dissemination during the 38th Annual Meeting of the German Society of Senology, Berlin, 14 June 2018
The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service
HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma
MEKK2 mediates aberrant ERK activation in neurofibromatosis type I
Reply to “CRISPR screens are feasible in TP53 wild‐type cells”
The impact of single tumor cell dissemination on individualized systemic breast cancer treatment
Tucatinib (Tukysa) bei HER2-positivem Brustkrebs : hochwirksame Behandlungsoption für metastasierte Patienten, auch bei ZNS-Metastasierung
Trastuzumab-Deruxtecan (Enhertu) - Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
Trastuzumab deruxtecan (Enhertu®) : Paradigmenwechsel: neue Optionen bei der Behandlung von Patient*innen mit nicht operablem, metastasiertem HER2-low Mammakarzinom
Circulating and Disseminated Tumor Cells in Breast Carcinoma : Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019
Update breast cancer 2023 Part 1 – early stage breast cancer
Attrition in the first three therapy lines in patients with advanced breast cancer in the German real-world PRAEGNANT registry
Circulating and Disseminated Tumour Cells in Breast Carcinoma : Report from the Consensus Conference on Tumour Cell Dissemination during the 38th Annual Meeting of the German Society of Senology, Berlin, 14 June 2018
The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service
HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma
MEKK2 mediates aberrant ERK activation in neurofibromatosis type I